The special 25th anniversary BIO-Europe 2019 global life science partnering event will be held November 11–13, 2019, in Hamburg, Germany.
The Annual Summit on Life Sciences IP Due Diligence to be held on November 14 and 15 in Boston, MA, is a one-of-a-kind, interactive forum where diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis for incumbent portfolios and those of potential targets.
LSX World Congress USA brings life sciences investment and partnering to Boston.
As lawyers and industry prepare for a possible no-deal Brexit, the uncertainty surrounding its impact runs like a core through the industry, as LSIPR’s Saman Javed discovers.
LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity.
While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.
A tie-up between four leading pharmaceutical companies, the UK government and a health charity has created the world’s largest genetic research project. LSIPR’s Rory O’Neill looks at a new frontier for life sciences.
Held during Boston’s week-long Biotech festival, BioPharm America promises its 4,500 delegates excellent knowledge, networking, and deal opportunities, says Guadalupe Rodriguez of EBD Group.
LSIPR provides a look behind the scenes of Shire Pharmaceuticals, the Irish company valued at £46 billion by its acquirer Takeda.
The evolution of antibody written description standards at the USPTO has put some drug portfolios at risk, say John Heithaus and Gerald Murphy of Birch, Stewart, Kolasch & Birch.